- Crunch time looms for BHP's bid buy Anglo American
- Kane to face old club Spurs for first time in Seoul
- Markets rise as traders cheered by China property plan
- Black farmers in Brazil changing views on coffee production
- Iran's President Raisi declared dead in helicopter crash
- Australia police arrest 554 in domestic violence crackdown
- South Korea, Britain host AI summit with safety top of agenda
- New president Lai vows to defend Taiwan's democracy
- Forever fad: Rubik says his cube 'reminds us why we have hands'
- Trump eyes witness stand as trial draws to a close
- Ryanair annual profit jumps on higher demand, fares
- High-priced Cummins, Starc face off as IPL enters playoffs
- Iran media says President Raisi died in helicopter crash
- Dominican Republic President Abinader re-elected to 2nd term
- New Taiwan president Lai hails 'glorious' democracy
- New Caledonia separatists defy French efforts to unblock roads
- Timberwolves knock out defending champion Nuggets, Pacers oust Knicks
- Trump biopic hits Cannes Film Festival
- Iran President Raisi's helicopter found, 'no sign of life'
- Three talking points ahead of 2024 French Open
- 'Haikyu!!': Comic heroes fuel Japan Olympic volleyball manga mania
- Timberwolves rally to knock defending champion Nuggets out of NBA playoffs
- London court set to rule on Julian Assange extradition
- Business and Bollywood votes in India election
- Pope calls anti-migrant attitudes at US border 'madness'
- Mexico aims to be big economic winner from US-China tensions
- Uncertain future for thousands after deadly Brazil floods
- Schauffele makes the putt of his life for first major win
- Wirtz returns to help unbeaten Leverkusen chase history
- Search for Iran's President Raisi after helicopter goes missing
- DeChambeau's powerful putting has him excited for US Open
- Taiwan to swear in new president as China pressure grows
- Atalanta can end 61-year wait for trophy in Europa League final
- Schauffele birdies final hole to capture PGA for first major win
- Guardiola casts doubt over long-term Man City future
- Hollywood icons Costner and Demi Moore make Cannes comeback
- Pacers shoot down Knicks to reach NBA Eastern Conference finals
- Schauffele birdies final hole, captures first major at PGA Championship
- McLaughlin powers to Indy 500 pole in all-Penske front row
- Monaco footballer tapes over LGBTQ badge
- Korda wins sixth LPGA title of year with win at Liberty National
- Pacers put on shooting show to down Knicks, reach NBA Eastern Conference finals
- US envoy touts 'potential' of Israel-Saudi deal in Netanyahu talks
- Dominicans vote for president in poll overshadowed by Haiti crisis
- Brest secure Champions League qualification, PSG win without Mbappe
- Mbappe absent as PSG win final Ligue 1 game
- Still exhausted after arrest, Scheffler closes with 64 at PGA
- Brest secure historic Champions League qualification
- France's Macron calls fresh emergency on New Caledonia unrest
- Taiwan swears in new president as China pressure grows
Diabetes drug shows promise against Parkinson's in clinical study
A drug used to treat diabetes slowed the progression of motor issues associated with Parkinson's disease, a study published in the New England Journal of Medicine said Wednesday.
Parkinson's is a devastating nervous system disorder affecting 10 million people worldwide, with no current cure. Symptoms include rhythmic shaking known as tremors, slowed movement, impaired speech and problems balancing, which get worse over time.
Researchers have been interested in exploring a class of drugs called GLP-1 receptor agonists -- which mimic a gut hormone and are commonly used to treat diabetes and obesity -- for their potential to protect neurons.
So far however, evidence of clinical benefits in patients has been limited and early studies have proved inconclusive.
In the new paper, 156 patients with early stage Parkinson's were recruited across France and then randomly chosen to receive either lixisenatide, which is sold under the brand names Adlyxin and Lyxumia and made by Sanofi, or a placebo.
After one year of follow up, the group on the treatment, which is given as an injection, saw no worsening of their movement symptoms, while those on the placebo did.
The effect was "modest" according to the paper and was noticeable only when assessed by professionals "who made them do tasks; walking, standing up, moving their hands, etc" senior author Olivier Rascol, a neurologist at Toulouse University, told AFP.
But, he added, this may just be because Parkinson's disease worsens slowly, and with another year of follow up, the differences might become much more stark.
"This is the first time that we have clear results, which demonstrate that we had an impact on the progression of the symptoms of the disease and that we explain it by a neuroprotective effect," said Rascol.
Gastrointestinal side effects were common on the drug and included nausea, vomiting and reflux, while a handful of patients experienced weight loss.
Both Rasol and co-author Wassilios Meissner, a neurologist at Bordeaux University Hospital, both stressed more study would be required to confirm safety and efficacy before the treatment should be given to patients.
Michael Okun, medical director of Parkinson's Foundation, told AFP that from a practical standpoint, the differences in patient outcomes were not clinically significant, but "statistically and compared to other studies, this type of difference should draw our interest and attention."
"Experts will likely argue whether this study meets a minimum threshold for neuroprotection and it likely does not," continued Okun, adding the weight loss side effect was concerning for Parkinson's patients.
The authors of the new study said they were looking forward to the results from other forthcoming trials that may help confirm their findings.
R.Adler--BTB